Bubonic Plague

Bubonic Plague

█ BRIAN HOYLE

A concern of health and defense officials is the possible deliberate introduction of plague—or the exploitation of plague—as a terrorist weapon. Plague causing microorganisms are highly lethal, highly transmissible, and relatively easy to develop as terrorist weapons.

Bubonic plague is transmitted via fleas infected with Yersinia pestis. Pneumonic plague results from plague bacterium investing lung tissue. Pneumonic plague exhibits an airborne form of transmission. Infection occurs from breathing aerosolized bacteria. Untreated pneumonic plague is highly lethal.

Bubonic plague is a disease that is typically passed from rodents to other animals and humans via the bite of a flea. The flea acquires the bacterium that causes the disease as it lives on the skin of the rodent. Humans can also acquire the disease by direct contact with infected tissue.

The bacterium Pasteurella pestis is also known as Yersinia pestis, after one of its co-discoverers, Alexandre Yersin.

Prior to 1970, both United States and Soviet biological weapons programs developed techniques that enabled weapons developers to aerosolize plague particles.

Bubonic plague is named because of the symptoms. The bacterial infection produces a painful swelling of the lymph nodes. These are called buboes. Often the first swelling is evident in the groin. During the Middle Ages, a pandemic of bubonic plague was referred to as the Black Death, because of the blackening of the skin due to the dried blood that accumulated under the skin's surface.

The bubonic plague has been a significant cause of misery and death throughout recorded history. The Black Death is only one of many epidemics of plague that extended back to the beginning of recorded history. The first recorded outbreak of bubonic plague was in 542–543. This plague destroyed the attempts of the Roman emperor of the day to re-establish a Roman empire in Europe. This is only one example of how bubonic plague has changed the course of history.

The plague of London in 1665 killed over 17,000 people (almost twenty percent of the city's population). This outbreak was quelled by a huge fire that destroyed most of the city.

The disease remains present to this day. In North America, the last large epidemic occurred in Los Angeles in 1925. With the advent of the antibiotic era, bubonic plague has been controlled in the developed world. However, sporadic cases (e.g., 10 to 15 cases each year) still occur in the western United States. In less developed countries (e.g., in Africa, Bolivia, Peru, Ecuador, Brazil) thousands of cases are reported each year.

The infrequency of bubonic plague outbreaks does not mean the disease disappears altogether. Rather, the disease normally exists in what is called an enzootic state. That is, a few individuals of a certain community (e.g., rodents) harbor the disease. Sometimes, however, environmental conditions cause the disease to spread through the carrier population, causing loss of life. As the rodent populations dies, the fleas that live on them need to find other food sources. This is when the interaction with humans and non-rodent animals can occur. Between outbreaks, Yersinia pestis infects rodents without causing much illness. Thus, the rodents become a reservoir of the infection.

Symptoms of infection in humans begin within days after contamination with the plague bacterium. The bacteria enter the bloodstream and travel to various organs (e.g., kidney, liver, spleen, lungs) as well as to the brain. Symptoms include shivering, nausea with vomiting, headache, intolerance to light, and a whitish-appearing tongue. Buboes then appear, followed by rupture of blood vessels. The released blood can coagulate and turn black.

If the infection is untreated, the death rate in humans approaches 75%. Prompt treatment most often leads to full recovery and a life-long immunity from further infection. Prevention is possible, since a vaccine is available. Unfortunately, the vaccine is protective for only a few months. Use of the vaccine is usually reserved for those who will be at high risk for acquiring the bacterial infection (e.g., soldiers, travelers to an outbreak region). Antibiotics such as tetracycline or sulfonamide are used more commonly as a precaution for those who might be exposed to the bacterium. Such use of antibiotics should be stopped once the risk of infection is gone, to avoid the development of resistance in other bacteria resident in the body.

The most effective way to prevent bubonic plague is the maintenance of adequate sanitary conditions. This acts to control the rodent population, especially in urban centers.

In 1970, a World Health Organization study concluded that deliberate dissemination of 110 lbs (50 kg) of aerosolized Y pestis over a city with a population of approximately 5 million people could potentially result in 150,000 cases of pneumonic plague. Half of these cases would require advanced medical care and approximately 20% would be expected to perish.

█ FURTHER READING:

BOOKS:

Campbell, G. L., and D. T. Dennis. "Plague and other Yersinia infections." In: D. L. Kasper, et al; eds. Harrison's Principles of Internal Medicine, 14th ed. New York: McGraw Hill, 1998.

Dennis, D. T., N. Gratz, J. D. Poland, and E. Tikhomirov. Plague Manual: Epidemiology, Distribution, Surveillance and Control. Geneva: World Health Organization, 1999.

Frist, W. H. When Every Moment Counts: What You Need to Know about Bioterrorism from the Senates Only Doctor. Lanham, MD: Rowman & Littlefield, 2002.

Henderson, D.A., and T.V. Inglesby. Bioterrorism: Guidelines for Medical and Public Health Management. Chicago: American Medical Association, 2002.

Inglesby, Thomas V. "Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague." Emerging Infections 5. Washington, D.C.: American Society for Microbiology Press, 2001.

PERIODICALS:

Kaufmann, A. F., M. I. Meltzer, and G. P. Schmid. "The Economic Impact of a Bioterrorist Attack: Are Prevention and Postattack Intervention Program Justifiable?" Emerging Infectious Diseases no. 3 (1997): 83–94.

SEE ALSO

Antibiotics
Biocontainment Laboratories
Biological and Toxin Weapons Convention
Biological Warfare
Biological Weapons, Genetic Identification
Bioterrorism, Protective Measures
Chemical and Biological Defense Information Analysis Center (CBIAC)
Chemical and Biological Detection Technologies
Pathogen Transmission
Pathogens
Weapons of Mass Destruction